nology includes
the United States: US FDA and University of California Davis. Asia: Hiyoshi
Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific
Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory,
Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy,
Poland.
Development of the XDS-CALUX(R) technology was funded in part by
Superfund Basic Research Program Grant (ES04699), and by Small Business
Innovation Research Grants from the National Institute of Environmental
Health Sciences (ES 08372-01 and ES 08372-02).
Additional information: XDS (http://www.dioxins.com) or call
1-888-D-I-O-X-I-N-S
(R) "Registered US Trademark and Patent Office"
'/>"/>SOURCE Xenobiotic Detection Systems Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women2.
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV3.
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder4.
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection5.
FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults6.
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria7.
UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies8.
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)9.
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older10.
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer11.
Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery